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mm Hg. Except for his short stature and early cataracts, no other
significant abnormalities were noted on physical examination.
Review of the laboratory data for the prior 4.5 years revealed that
serum electrolytes, liver chemistries, and hemogram were always
within normal limits. The only consistent abnormality was an elevated
serum cholesterol, which varied between 256 mg/dl and 350 mg/dl.
From age 13 to 17, the BUN ranged between 11 mg/dl and 16 mg/dl, and
the serum creatinine between 0.4 mg/dl and 0.9 mg/dl. Dipstick test
results for urine albumin varied considerably but generally were nega-
tive from ages 13 to 16 years, although occasional tests during this time
period showed 1+ to 2+ albumin. From age 16 to 17.5, the urine
albumin was consistently I + to 2+. Twenty-four hour total protein
excretion ranged from 200 to 800 mg.
Because his body weight was recorded on every clinic visit, it was
possible to calculate the endogenous creatinine clearance from the
equation:
—
(140 — age) wt in kg
Ccr
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A 17-year-old Hispanic male was referred to the Adult Renal Clinic of
Montefiore Medical Center because of progressive proteinuria and
hypertension. The patient developed insulin-dependent diabetes mclii-
tus (IDDM) at the age of 2 years while living in Puerto Rico. He had
been a patient at several other health facilities in the Bronx and was
referred at age 13 to the Pediatric Diabetes Service at Montefiore
Medical Center. Prior to that time, his diabetic control had been poor,
and he had been hospitalized several times for diabetic ketoacidosis.
Extensive, detailed medical records were available for him for ages
13 to 17. During that 4.5-year period, his glycemic control was some-
what improved, and only one hospitalization was needed to treat a
minor skin infection. Compliance with the prescribed diet was very
poor, however. Blood glucose measurements at home ranged between
120 and 300 mg/dl, most often in the hyperglycemic range, and the
urinary glucose was 1 + to 3+ on every clinic visit. Hemoglobin A1
was measured frequently during the 4.5 years, and was 2 to 3 times
higher than the upper limit of normal on each occasion. The patient
refused to administer insulin to himself and was injected by his mother
or older sister; at times, however, he refused the injections. He
attended a special school for physically handicapped children because
of bilateral lenticular opacities; he was also thought to be mildly
retarded. His height and weight were at the lower limits of normal for
his age. Blood pressure was recorded in the range of 90—110 mm Hg
systolic and 6040 mm Hg diastolic at ages 13 to 15. Beginning at age
15.5, his blood pressure rose to the range of 140-156 mm Hg systolic
and 88 to 108 mm Hg diastolic. At age 17, just prior to his first
examination in the Adult Renal Clinic, his blood pressure was 145/88
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where Ccr refers to creatinine clearance and Scr refers to serum
creatinine. (Creatinine clearance also was measured on several occa-
sions from 24-hour urine collections, but the urine collections were
considered incomplete.) At age 14, his serum creatinine was 0.4 mg/dl
and body weight was 40 kg; the calculated creatinine clearance was 175
mi/mm. At age 15, the serum creatinine was 0.6 mgldl and body weight
was 45 kg; the calculated creatinine clearance was 130 mI/mm. At age
16, serum creatinine was 0.8 mg/dl and weight was 50 kg; the calculated
creatinine clearance was 108 mI/mm. When he was referred to the Adult
Renal Clinic at age 17, the serum creatinine was 0.9 mg/dl and body
weight was 53.2 kg; calculated creatinine clearance was 101 mi/mm.
The fall in creatinine clearance from 175 mI/mm to 101 mI/mm occurred
in spite of the increase in body weight and height. Thus, there was clear
evidence that hyperfiltration was present from ages 14 to 15, but
between 15 and 16 years of age, at approximately the same time that
hypertension developed, his creatinine clearance fell progressively to
less than 110 mI/mm.
In the Adult Renal Clinic, physical examination revealed a blood
pressure of 150/92 mm Hg. Aside from short stature and bilateral
cataracts, the remainder of the physical examination was negative.
Urinalysis showed 2+ albumin and 4+ glucose, but was negative on
microscopic examination. Serum creatinine was 0.9 mg/dl; BUN, 16
mg/dl; serum cholesterol, 256 mgldl; and glucose, 155 mg/dl. Enalapril
therapy was initiated, 2.5 mg daily, and he was directed to follow a 2 g
sodium diet. When seen one month later, the blood pressure was 110/78
mm Hg. The serum creatinine had risen to 1.1 mg/dl and the BUN to 20
mgldl. A urine dipstick test was negative for albumin.
The patient has continued to be followed in the Adult Renal Clinic for
3 years. During that time, he has continued taking enalapril, 2.5 to 5.0
mg daily, except for brief periods when his prescription ran out. His
blood pressure has varied from 118/55 mm Hg (while taking medication)
to 160/110 mm Hg (while not taking medication). The urinary albumin
has tended to parallel blood pressure, being trace to 1+ when the blood
pressure was normal, to 2+ when hypertension was present. The serum
creatinine has risen to 1.4 mg/dl and the BUN to 22 mgldl. Serum
electrolyte values remain normal. Total urinary protein excretion has
risen to 1 g/day. Serum cholesterol remains elevated, above 300 mg/dl.
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Lipoprotein analysis revealed low-density lipoprotein, 222 mgldl; high-
density lipoprotein, 48 mg/dl; and triglycerides, 196 mg/dl. At age 20,
his weight is 58 kg, and the calculated creatinine clearance is 69 mI/mm.
Discussion
DR. NORMAN BANK (Director, Renal Division, Montefiore
Medical Center, and Professor of Medicine, Albert Einstein
College of Medicine, Bronx, New York): This young patient
with IDDM illustrates the typical course of diabetic nephrop-
athy with early renal hyperfiltration, progression to proteinuria,
hypertension, and declining GFR. This progression has been
described by a number of investigators [1—91. Several factors
might have contributed to the course of his disease, including
poor metabolic control, lack of adherence to a suitable diet,
hypercholesterolemia, and unsatisfactorily controlled hyperten-
sion. The prognosis is guarded, because progression to end-
stage renal disease within the near future is a virtual certainty.
Hyperfiltration, a common finding in early IDDM, is thought
to contribute importantly to renal injury [8, 9]. Understanding
the one or more mechanisms responsible for hyperfiltration of
early IDDM is important; the hope is that preventing hyperfil-
tration will delay the onset, slow the progression, or even
prevent diabetic nephropathy. In this Forum, I will discuss the
experimental findings relating to mechanisms of hyperfiltration.
Many theories have been proposed and tested, often with a lack
of agreement among investigators. It seems likely, in fact, that
more than one mechanism contributes to diabetic hyperfiltra-
tion.
Careful measurements of renal function in young patients
with IDDM reveal that glomerular filtration rate (GFR) and
renal plasma flow (RPF) are often higher than in a matched
group of normal subjects. For example, using '251-iothalamate
and '311-Hippuran, Christiansen et al found that GFR was 27%
higher and RPF 20% higher in a group of 13 diabetic patients
than in normal controls [I]. The study group had had diabetes
less than 7 years. These observations agree with findings by
other investigators [2—7], who used a variety of techniques to
measure renal function. In most studies, both GFR and RPF
were elevated, although Ditzel and Junker found RPF to be
slightly lower than in normal controls and GFR to be higher,
resulting in a high filtration fraction [2]. Similarly, Mogensen
and Andersen found GFR to be elevated in young diabetics, but
not RPF [5]. I should note that certain pitfalls exist in measuring
renal function accurately in diabetic patients. For example,
autonomic dysfunction of the bladder could interfere with
complete emptying, and increased extrarenal clearance of in-
jected Cr-EDTA could confound the measurement [10]. It
seems unlikely, however, that these potential pitfalls can ac-
count for the preponderance of evidence pointing to an early
functional abnormality in patients with IDDM, an alteration
characterized by elevation of GFR and RPF.
Elevated GFR and RPF also have been found in studies of
rats with experimental IDDM in which both whole-kidney and
single-nephron GFR (SNGFR) are elevated within the first few
weeks of induction of diabetes. Using micropuncture tech-
niques, Hostetter et al studied rats with streptozotocin (STZ)-
induced diabetes that were given insulin to partially ameliorate
hyperglycemia. Such rats have elevated levels of glomerular
filtration rate and plasma flow (SNGFR, QA) and reduced levels
of the afferent arteriolar resistance (RA), yielding normal values
Table 1. Abnortmalities in diabetes melitus that might contribute to
renal hyperfiltration
Vasoactive hormones
Increased production of vasodilatory prostaglandins
Impaired responsiveness to thromboxane
Increased renal kalikrein production
Abnormal responsiveness to norepinephrine
Increased levels of atrial natriuretic hormone
Abnormal renin-angiotensin system
Insulinopenia and abnormal calcium metabolism
Increased poyol pathway metabolism
Hyperglycemia and extracellular fluid volume expansion
for the ultrafiltration coefficient (Kf) [1 1]. Jensen et al reported
similar findings, except that intratubular pressure was lower
than normal and resulted in a higher transglomerular hydraulic
pressure gradient [12]. Michels et al also found SNGFR and QA
to significantly exceed control values [13].
Data on the effect of insulin treatment on renal hemodynam-
ics have been conflicting; some investigators found GFR and
RPF to be reduced below normal if insulin was not administered
[11, 13]; others found that strict metabolic control with insulin
reduced hyperfiltration [14]. In our laboratory, hyperfiltration
was present whether or not insulin was given [15—18]. With
regard to glomerular capillary pressure (P0), findings have
varied considerably among different laboratories. Values range
from normal, to slightly elevated, to markedly elevated [11, 12,
14, 15, 18, 19]. The reason for these differences in hemodynam-
ics and P0 in experimental diabetes is not clear; possible
explanations include differences in volume status, prior dietary
intake of protein and salt, the type of anesthetic used for
surgery, and arterial blood pressure at the time of micropunc-
ture study. Untreated diabetic rats are polyuric and catabolic
and fail to gain weight. Therefore, volume status is often
uncertain. Insulin treatment can ameliorate the polyuria; nev-
ertheless diabetic rats usually do not grow at the same rate as do
normal rats. Because of this difference, whole-kidney GFR
should be compared in rats of the same size and age. In lieu of
such a protocol, some authors correct their data for body
weight, that is, GFRI100 g body weight. When this maneuver is
performed, GFR is clearly higher in diabetic than in normal
rats. However, when expressed per gram of kidney weight,
GFR in diabetic rats is often in proportion to the larger kidney
weight. Single-nehpron measurements, which in most studies
are not corrected either for kidney weight or body weight,
consistently show striking absolute elevations of SNGFR, QA.
and single-nephron blood flow (SNBF), a marked decrease in
RA, and no change in Kf [11, 15—18]. Efferent arteriolar resis-
tance (RE) also tends to be low, but this reduction, less marked
than the fall in RA, is not statistically significant [11]. What is
certain from the findings in rats is that renal vascular resistance
is low and, as a result, blood flow through the kidney is
increased. The rise in plasma flow is largely responsible for the
hyperfiltration, although a rise in GC also might contribute.
Table 1 outlines the proposed mechanisms of hyperfiltration
in diabetes. I should say at the outset that other vascular beds
throughout the body also show decreased resistance to blood
flow in early IDDM, and that this finding strongly implies a
generalized mechanism rather than one restricted to the kidney.
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Vasoactive hormones
Vasodilatory prostaglandins contribute to the regulation of
renal hemodynamics, most clearly under conditions in which
the activity of vasocontrictor hormones is increased. Much
interest has been focused on the possible role of vasodilatory
prostaglandins in the hyperfiltration of early IDDM. Several
laboratories have found that PGE2 production by glomeruli or
mesangial cells from diabetic rats is greater than normal [20—
23]. Barnett et a! found that glomeruli from rats with strepto-
zotocin-induced diabetes of 3 weeks duration produced more
PGE2 under both basal and stimulated conditions than did
normal glomeruli [20]. In contrast, glomeruli from BB rats with
genetic diabetes produced normal amounts of PGE2. In spite of
the increased PGE2 production, planar surface area of glomeruli
decreased in response to added angiotension II, vasopressin,
and norepinephrine in a fashion comparable to that seen in
normal glomeruli. These results argued against the view that
excess prostaglandins interfere with diabetic glomeruli's re-
sponsiveness to vasoconstrictor hormones. Schambelan et al
also found that glomeruli from rats with STZ-induced diabetes
produce more prostaglandins than do normal glomeruli [21].
Kreisberg and Patel showed that mesangial cells cultured from
diabetic rat glomeruli produced predominantly PGI2 instead of
PGE2, in contrast with normal mesangial cells [22]. The total
amount of prostaglandins produced by diabetic mesangial cells
was greater than that produced by normal cells, and this amount
was attenuated by the addition of insulin to the culture medium.
Craven and colleagues measured basal PGE2 , 6-keto PGFI,,
and thromboxane B2 production by glomeruli isolated from
streptozotocin diabetic rats 9 to 15 days after streptozotocin
injection [23]. Levels of all three prostaglandins were elevated.
Incubation of the diabetic glomeruli with insulin for 2 hours
reduced prostaglandin production to normal. In contrast, gb-
meruli from rats that had been diabetic for 25 to 28 days did not
produce more prostaglandins than did control glomeruli. Nev-
ertheless, hyperfiltration in the intact animals was present at
both 9 to 15 days and at 25 to 28 days. Thus, hyperfiltration
could be dissociated from excess prostaglandin production.
Studies of cyclooxygenase inhibition in experimental diabetic
animals have yielded conflicting results. Craven et al found that
indomethacin reduced hyperfiltration in rats 9 to 15 days after
induction of diabetes but did not do so 25 to 28 days after
induction of diabetes [23]. These researchers suggested that
increased prostaglandins had been contributing to hyperfiltra-
tion during the first 2 weeks of diabetes, but that after that,
hyperfiltration appeared to be independent of the prostaglandin
production rate. Similarly, Moe! and coworkers found that
aspirin normalized hyperfiltration in rats with diabetes of 8 days
duration but raised GFR in rats 16 weeks after the induction of
diabetes [24]. Jensen and colleagues reported that indomethacin
reduced SNGFR markedly in rats 3 months after the induction
of STZ diabetes [19]. The animals in that study did not have
hyperfiltration prior to indomethacin administration, however,
nor did they manifest any of the other glomerular hemodynamic
abnormalities usually found in diabetic rats with hyperfiltration.
The animals had been receiving insulin prior to the study, and
the added insulin might have reduced prostaglandin production
and decreased GFR to normal before the rats were given
indomethacin. Kirschenbaum and Chaudhari found that GFR in
rats with diabetes of 28 days duration was elevated, but that
continuous administration of indomethacin during the 28 days
prevented a rise in GFR [25]. Glomerular prostacyclin produc-
tion, measured after 7 days of diabetes, was increased, whereas
thromboxane production was decreased. They postulated that
hyperfiltration was mediated by an imbalance of prostanoid
biosynthesis. In our laboratory, the effect of acute intravenous
administration of indomethacin was studied in rats 7 to 10 days
after the onset of STZ-induced diabetes [16]. These animals
were clearly hyperfiltering prior to indomethacin infusion.
There was no significant effect on either whole-kidney GFR or
SNGFR over the 3 hours after administration of the indometh-
acm, even though PGE2 in the urine and early proximal tubular
fluid fell markedly. We concluded that vasodilatory prostaglan-
dins were not responsible for hyperfiltration. These autocoids
are not stored, so inhibition of their synthesis causes acute
depletion. If vasodilatory prostaglandins played a central role in
hyperfiltration, GFR should have fallen quickly with cyclooxy-
genase inhibition.
The role of increased vasodilatory prostaglandins in mediat-
ing hyperfiltration in human diabetes also is not clear. Esmatjes
and colleagues inhibited cyclooxygenase by infusing lysine
acetylsalicylate into 7 humans with recent-onset IDDM who
had hyperfiltration [26]. Both GFR and RPF fell in all but one
subject. However, both GFR and RPF remained significantly
higher than in the control subjects. The cyclooxygenase inhib-
itor had no effect in normal subjects. For 3 days prior to renal
hemodynamic studies, Hommel et al gave indomethacin to 8
patients with IDDM and found that GFR fell in 7 [27]. These
patients did not clearly have hyperfiltration prior to indometh-
acm administration, the average GFR being 120 mllmin/1 .73 m.
Moreover, they most likely had significant glomerulopathy,
because albuminuria was present in all of them. In contrast,
Christiansen et al found no effect of 3 days of indomethacin
administration on either GFR or RPF in 9 patients with early
IDDM [28].
A summary of the experimental results of cyclooxygenase
inhibition on the hyperfiltration of diabetes in humans and
animals is presented in Table 2. The reasons for the conflicting
results are uncertain, but the duration of diabetes, the degree of
glucose control, volume status at the time of study, and the
duration of cyclooxygenase inhibition might have contributed
to the discrepancies. Volume contraction is known to stimulate
both prostaglandin and angiotensin II production. Renal hemo-
dynamic control becomes dependent on the interplay of these
two vasoactive systems in volume-contracted states, whereas
this is not the case in euvolemic or volume-expanded states.
Because volume status varies considerably in diabetes, differ-
ences in salt and water balance possibly contributed to the
inconsistency of findings with cyclooxygenase inhibition. The
contribution of vasodilatory prostaglandins to the hyperfiltra-
tion of IDDM thus remains an unsettled question.
A rapidly growing body of information indicates that vascular
endothelium plays an important role in the regulation of smooth
muscle tone. Constricting (for example, endothelin) and relax-
ing (such as endothelium-derived relaxing factor, EDRF) sub-
stances are both released by endothelial cells in response to
various agonists that react with receptors on cell surfaces. The
vasoactive products are thought to act locally on the underlying
vascular smooth muscle cells and thus produce changes in tone.
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Human studies
Duration of
GFR RPF Rx Ref.
L. Acute 26
— 3days 27
—* —* 3days 28
Rat studies
GFR SNGFR
Duration of
diabetes Ref.
9—15 days 23
— — 25—28 days 23
— 8days 24
1' — 16 weeks 24
. 12 weeks 19
I. — 4weeks 25
— — 2—3 weeks 16
II
II
/<00
A disturbance in the balance of these constricting/relaxing
products could play a role in the hyperfiltration of IDDM [291.
Studies of aortic rings from diabetic rabbits and rats show
that relaxation in response to acetyicholine or histamine (acti-
vators of EDRF) is subnormal [30, 31]. Scanning electron
microscopy of the endothelium in the rat studies revealed
swollen cells with raised or sloughed nuclei [31]. Tesfamariam
and colleagues confirmed that acetylcholine-induced relaxation
of aortae is impaired in rabbits with alloxan-induced diabetes,
but that this abnormality is corrected by the addition of indo-
methacin [32]. Thromboxane synthesis was increased in dia-
betic aortae with an intact endothelium; the findings therefore
suggested that the increased thromboxane prevented normal
relaxation when EDRF was stimulated by acetylcholine. The
same group of investigators found that aortae from normal
rabbits exposed to high glucose concentrations in vitro behaved
in he same manner as did aortae from diabetic animals [33].
Thus, hyperglycemia per se appeared to be responsible for the
increased thromboxane synthesis and thus also for the failure of
a normal relaxation response to EDRF.
Katayama et al reported that urinary thromboxane B2 excre-
tion is higher in diabetic patients than in controls [34, 35]. We
also found that urinary thromboxane B2 excretion is higher in
rats with STZ-induced diabetes than in normal rats and that the
level rises even further when serum cholesterol is elevated by
feeding a diet containing 4% cholesterol (Fig. 1, unpublished
observations). In spite of the marked increase in thromboxane
B2 excretion, there was little or no effect on hyperfiltration. In
contrast, when normal rats are made hypercholesterolemic, the
renal blood vessels constrict significantly; this constriction is
mediated by increased thromboxane A2 production [36]. We
further studied the failure of diabetic rats to respond to in-
creased thromboxane A2 production by infusing a thromboxane
agonist (U 46619) into the aorta above the renal arteries. As
Figure 2 shows, the decrease in RBF, GFR, and SNGFR was
smaller in diabetic rats than in normal controls. When glycemic
control was improved by the administration of long-acting
ultralente insulin daily, the response to U 46619 returned to
normal.
These observations suggest that renal blood vessels of dia-
betic rats are partially resistant to the vasoconstrictor effect of
both endogenous and exogenously administered thromboxane.
The reason for this resistance is uncertain, but Wilkes and
coworkers reported that glomerular thromboxane A2 receptors
are reduced in glomeruli from diabetic rats [37]. Yanagisawa et
al recently reported that insulin markedly accentuates the
contractions of coronary arteries from normal pigs stimulated
by a stable analogue of thromboxane A2 in vitro [38]. Insulin did
not affect the contractions evoked by several other hormones.
Thus it is possible that either the absence of insulin or de-
creased thromboxane A2 receptors in diabetes impairs renal
vascular responsiveness to thromboxane A2. The cause of the
abnormality in receptors and the impaired response to throm-
boxane A2 in the absence of insulin is not known at present. It
seems likely, however, that these disturbances will prove
important in the hyperfiltration of diabetes.
Few studies of the role of kallikrein in diabetes have been
carried out, but Jaffa and colleagues found that renal tissue
levels and urinary excretion of kallikrein are reduced in un-
treated rats with STZ-induced diabetes [39]. This reduction was
caused by decreased renal synthesis of pro-kallikrein, and this
abnormality was corrected by insulin treatment. These re-
searchers also studied the role of kallikrein in the same rat
model, but this time using animals treated with insulin [40].
Kallikrein excretion was higher in the study rats than in
controls, and this increase correlated with a higher GFR and
RPF. The GFR was reduced to normal when the diabetic rats
were treated with aprotinin, an inhibitor of kallikrein produc-
tion, on the day before and on the day of study. We infused
aprotinin acutely into the renal artery of rats with STZ-induced
diabetes and hyperfiltration using a dose known to inhibit
urinary active and total kallikrein by more than 90% [16]. We
Table 2. The effect of cyclooxygenase inhibition on hyperfiltration of
diabetesa
2000
1600
°- 1200
x
I—
>-
ca 800C
400
0
P < 0.05
a Abbreviations: GFR, glomerular filtration rate; RPF, renal plasma
flow; Rx, cyclooxygenase inhibitor; SNGFR, single-nephron glomeru-
lar filtration rate.
Normal rats Diabetic rats Normal rats Diabetic rats
ND ND CSD CSD
Fig. 1. Urinary thromboxane (TxB2) excretion in normal and diabetic
rats. ND, normal diet; CSD, cholesterol-supplemented diet.
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Fig. 2. Renal hemodynamic response to intrarenal infusion of throm-
boxane agonist U 46619 in normal and diabetic rats.
found no significant effect on urine flow, sodium excretion,
GFR, or SNGFR. Thus, as is the case with prostaglandin
inhibitors, different results are obtained with kallikrein inhibi-
tors, depending on whether insulin is administered and whether
the inhibitor is given acutely or chronically. The failure of acute
inhibition of kallikrein to ameliorate the hyperfiltration in this
rat model [16] implies that bradykinin is not the proximate
cause of hyperfiltration. If it were, acute inhibition should have
promptly corrected the hyperfiltration.
Norepinephrine is one of the major vasoactive hormones that
constrict renal blood vessels. Therefore, a decrease of circulat-
ing levels, of synthesis at nerve endings, or of receptors might
lead to impaired renal vascular tone. Christensen reported that
plasma catecholamine concentration (mainly norepinephrine)
was normal in long-term diabetic patients without neuropathy
[41]. Beretta-Piccoli et al found the response of plasma norep-
inephrine to upright posture in diabetic subjects to be normal in
most cases [42]. Likewise, epinephrine levels in diabetic sub-
jects were normal. No difference in endogenous creatinine
clearance was found when patients were grouped according to
low versus normal plasma norepinephrine concentrations [421.
Studies of isolated vascular smooth muscle sensitivity and
reactivity to norepinephrine in diabetic animals have yielded
variable and inconsistent results. A number of different vascu-
lar beds have been studied, including the isolated aorta [43, 44]
mesenteric arteries [45], and blood vessels of the hind limb [46,
47]. Both increased and decreased sensitivity and maximum
responsiveness of these vessels to norepinephrine have been
reported. Most studies report increased sensitivity to norepi-
nephrine (decreased threshold), which is consistent with a
postganglionic neuroeffector sympathetic defect, analogous to
denervation hypersensitivity [47]. Some of the variability in
vascular responses to norepinephrine can be explained by
differences in the species studied, the duration and severity of
diabetes and the particular vascular bed tested. Responses also
vary depending on whether insulin has been administered. For
the most part, isolated blood vessels, aortic rings, and cells in
culture are highly unphysiologic preparations, because they
lack innervation and blood flow is absent. Moreover, the
contractile response depends, among other things, on the
calcium concentration in the bathing medium. For example,
Owen and Carrier demonstrated that aortic rings from diabetic
rats were supersensitive to norepinephrine but that the re-
sponse depended on the calcium concentration in the bathing
medium [48]. In addition, rings from rats that had been diabetic
for 28 to 35 days yielded greater maximum contractile force at
all calcium concentrations than did rings from rats that had had
diabetes for only 14 to 20 days. MacLeod and McNeill found
that the aortae from "100-day" diabetic rats were supersensi-
tive to norepinephrine, but this sensitivity was not observed 180
days after the onset of diabetes [44]. At 360 days, however,
sensitivity and responsiveness to norepinephrine again were
increased. On the other hand, Ramanadham and coworkers
found that the thoracic aorta from rats with 4 weeks of
STZ-induced diabetes exhibited decreased responsiveness to
norepinephrine [43]. Morif studied arterioles of the cremaster
muscle from rats with STZ-induced diabetes and found that
larger arterioles responded normally to norepinephrine after 2
to 16 weeks of diabetes [49]. Smaller arterioles exhibited
hypersensitivity early in the course of diabetes, but the re-
sponse returned to normal at a later stage in the disease. From
these several studies, it appears that the stage of diabetes as
well as the vessel size and location influence the vascular
response to norepinephrine. In patients with diabetes, Christ-
lieb measured blood pressure sensitivity and reactivity to
infused norepinephrine and found both to be increased [50]. In
agreement, Beretta-Piccoli and Weidmann found that the base-
line plasma norepinephrine was similar in diabetic and normal
subjects, and that the pressor and threshold doses to infused
norepinephrine were lower in diabetics [51]. Christlieb found
reduced plasma levels of norepinephrine in rats with alloxan
diabetes [52]. Reduced tissue levels of catecholamines have
been reported for the tail artery of rats with STZ-induced
diabetes [43, 53]. Most of the evidence thus indicates that blood
vessels from diabetic animals are hyperreactive to exogenous
norepinephrine, perhaps because of impaired endogenous syn-
thesis or release of norepinephrine. Unfortunately, none of the
studies in humans or animals has correlated the degree of
sensitivity and reactivity to exogenous norepinephrine with
renal hemodynamics. Although it is possible that diabetes might
0
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have impaired renal nerve synthesis or storage of catechol-
amines, or reduced receptors, further studies are needed to
clarify these issues.
The administration of atrial natriuretic peptide (ANP) causes
renal vasodilation and increases GFR. Therefore it is reason-
able for us to consider excess endogenous ANP as a mediator of
chronic hyperfiltration. Atrial natriuretic peptide is elevated in
the plasma of diabetic animals [54] and humans [551, and the
levels vary inversely with the degree of metabolic control of
glucose [56]. Ortola et al studied the relationship between GFR
and ANP in diabetic rats [54]. In animals with moderately
controlled diabetes (average blood glucose, 326 mg/dl), ANP
was 280 pglml, whereas in animals with tightly controlled
diabetes (average blood glucose, 85 mg/dI), ANP was 158 pg/mI.
The GFR was elevated in the moderately controlled group and
was completely normal in the tightly controlled group. When
these authors infused an antiserum directed against ANP into
hyperfiltering diabetic rats, they found a prompt decline in GFR
and RPF to normal with no alteration of blood pressure or blood
glucose. Their observations provide strong support for the view
that ANP is the mediator of hyperfiltration in diabetic rats.
Atnal natriuretic peptide is elevated in volume-expanded con-
ditions, and its exogenous administration causes systemic vaso-
dilation, suppression of plasma renin activity [57, 58], de-
creased aldosterone production [59], and decreased plasma
aldosterone [57]. Infusion of ANP in normal rats raises glomer-
ular capillary pressure [60].
Some of the hemodynamic and hormonal abnormalities of
volume-expanded diabetic animals can be mimicked by ANP
administration. However, several significant differences exist
between the effects of exogenous ANP on renal hemodynamics
and the hyperfiltration in diabetes. First, in normal dogs, Maack
et al found that intravenous ANP lowered RPF at the same time
that GFR and sodium excretion rose [57, 61]. Decreased RPF is
not characteristic of diabetic hyperfiltration. Dunn et al [60] and
Huang et al [62] found similar results when they infused ANP
intravenously into normal rats. The GFR rose by 20% to 45%,
whereas renal and glomerular plasma flow remained stable. The
rise in GFR could be entirely accounted for by a rise in PGC
[60]. Glomerular plasma flow is typically elevated in rats with
early STZ-induced diabetes. Schnermann et al found that
stop-flow pressure (an indirect measure of glomerular capillary
pressure) rose by 10 mm Hg when either atrial extract or
synthetic atriopeptin II was infused into normal rats [63]. The
increase was due to afferent arteriolar dilation, with little or no
dilation of the efferent arteriole. Marin-Grez et a! measured
afferent and efferent arteriole diameters directly by intravital
microscopy and found that ANP dilated the afferent arteriole
but decreased the diameter of efferent arterioles by 10% [64].
This profile of glomerular hemodynamics is also not character-
istic of diabetes, in which both afferent and efferent arteriolar
resistances are low, plasma flow is increased markedly, and
P is increased moderately or not at all. Finally, low-dose
infusion of ANP in normal humans, at rates that raised plasma
ANP from 28 to 360 pg/mI (levels comparable to those of
endogenous ANP in diabetic rats), slightly decreased GFR and
RPF at the same time that sodium excretion rose and plasma
renin activity (PRA) and angiotensin II levels decreased [65].
Because the effects of exogenous ANP on glomerular hemody-
namics differ significantly from those in diabetic rats, the role of
ANP as the major mediator of diabetic hyperfiltration is ques-
tionable. Atrial natriuretic peptide might contribute to hyperfil-
tration, however, in that it antagonizes the vasoconstrictor
actions of both angiotensin II and norepinephrine [55, 66].
Because angiotension II is a major constricting hormone of
blood vessels in the kidney, considerable attention has been
focused on abnormalities in the renin-angiotensin system as a
possible contributor to hyperfiltration in IDDM. Christlieb
showed in rats with alloxan-induced diabetes that renal and
plasma renin activity are reduced. Angiotensin II prompted an
increased blood pressure response, but norepinephrine did not
[52]. Increased blood volume might have been the cause of the
lower PRA. In diabetic humans with poor glucose control,
Christlieb and colleagues found blood volume to be somewhat
higher than after improved metabolic control, although PRA did
not change significantly [67]. Ballerman et al found that plasma
renin concentration (PRC) was lower in diabetic rats than in
normal controls, but insulin therapy normalized PRC [68]. In
addition to a reduction in PRA, angiotensin II receptor density
is reduced in diabetic glomeruli [18, 68]. The receptor density
varies directly with dietary salt intake and correlates inversely
with PRC [68], as in normal rats. However, the absolute density
remains low under all conditions studied [68]. These observa-
tions support the concept that a combination of low circulating
angiotensin II and decreased glomerular angiotensin II recep-
tors is responsible for hyperfiltration in IDDM. Several studies
suggest, however, that the decrease in angiotensin II receptors
is not sufficent to prevent the vascular response to exogenously
administered angiotensin II. In our laboratory, administration
of angiotensin II into the renal artery of rats with STZ-induced
diabetes resulted in a fall in SNGFR and QA and a rise in
afferent arteriolar resistance without any change in GC; these
results were quantitatively similar to those in normal control
rats that were chronically expanded due to the ingestion of large
amounts of sodium chloride [16]. We also found that restriction
of dietary sodium intake reduced GFR and RPF from supernor-
mal to normal levels [17] (Fig. 3). This effect apparently was
mediated by stimulation of the endogenous renin-angiotensin
system, because acute infusion into the renal artery of sarala-
sin, a receptor antagonist of angiotensin II, abruptly returned
SNGFR and QA to supernormal levels (Fig. 4). Thus, the renal
angiotensin II receptors apparently were capable of responding
to stimulated levels of endogenous angiotensin II, in spite of the
fact that receptor density would be expected to fall further as
endogenous angiotensin II rose [68]. In 10 patients with IDDM
and 10 matched controls, Bjorck measured the response of GFR
and RPF to intravenous infusion of angiotensin II at 0.5 to 1.5
ng/kg/min [691. He found that GFR and RPF, which were
elevated in the diabetic subjects, fell equally in the two groups,
indicating that vascular responsiveness to exogenous angioten-
sin II was not impaired in the diabetic humans. Taken together,
these observations suggest that the reduced glomerular angio-
tensin II receptor density does not in itself account for diabetic
hyperfiltration. Some studies of non-renal vascular beds in
diabetic animals disclosed increased sensitivity and responsive-
ness of blood pressure and muscle arterioles to exogenously
administered angiotensin II [50, 70]. Beretta-Picolli and Weid-
mann reported that the angiotensin II pressor dose was lower in
nonazotemic diabetic patients than in normal subjects [51].
Diabetic hyperfiltration thus does not appear to be due to the
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studied in vitro were markedly decreased in response to potas-
sium chloride administration [71]. The decrease was completely
reversed in animals treated with insulin. Using rat glomerular
mesangial cells in culture, Kreisberg found that insulin was
necessary for a contractile response to angiotensin II [72].
Evidence supports the view that insulin is important for entry of
calcium into certain cells. For example, Cohen et al found that
calcium suppressed renin release in isolated, perfused, normal
rat kidneys, but that this suppression occurred only when
insulin was present in the perfusate [73]. The effect of insulin
200 was blocked by the addition of a calcium-channel blocker
___________________________ 150 (verapamil) to the perfusate. Mueller reported that insulin
restored vascular contraction in animals with alloxan-induced
_____________________________
100 diabetes in response to various stimuli, all of which involve
transmembrane calcium flux or mobilization of intracellular
50 calcium [74]. Gotzsche reported the absence of myocardial
contraction of isolated perfused diabetic rat hearts in response
to isoproterenol. Also, calcium uptake is absent [75]. Providing
insulin either to the animals or to the isolated in-vitro heart
preparation reversed these abnormalities.
We studied the effect of intrarenal insulin and calcium infu-
sion on hyperfiltration in diabetic rats [15]. Low concentrations
of insulin and calcium, either singly or in combination, had no
effect on GFR or SNGFR in normal rats (Fig. 5). In diabetic
rats, infusion of low-dose insulin into the renal artery also had
no effect on the elevated GFR or SNGFR. But when calcium
was added to the insulin infusion, GFR and SNGFR both
promptly fell to the normal range. This fall was accompanied by
a normalization of P and a decrease in UNaV and urine flow
[15]. The effects of the combined infusion of calcium and insulin
were reversed immediately when we added verapamil to the
intrarenal infusion [15]. These observations strongly suggest
that insulin deficiency impairs calcium uptake by renal vascular
smooth muscle cells. Thus, insulin deficiency per se could play
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kidney's impaired responsiveness to angiotensin II. The possi-
bility remains, however, that low circulating and/or renal tissue
levels of angiotensin II, perhaps related to ECF volume expan-
sion, contribute to diabetic hyperfiltration.
Effects of insulin and calcium on vascular smooth muscle
Several observations indicate that insulin plays an important,
direct role in smooth muscle and myocardial contraction.
Therefore, insulin deficiency per se needs to be considered as a
mechanism contributing to diabetic hyperfiltation. Pfaffman and
colleagues found that contractions of aortae from diabetic rats
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an important role in the hyperfiltration of IDDM. In addition,
vasoactive hormones that initiate calcium entry into vascular
smooth muscle cells may lose their effectiveness in the absence
of insulin.
The polyol pathway
A major area of interest with regard to the complications of
diabetes is the cellular accumulation of sorbitol and the deple-
tion of myoinositol [761. These changes occur in several tissues
that contain the enzyme aldose reductase. Glucose is converted
to sorbitol via aldose reductase activity, and the sorbitol is then
converted to fructose via activity of sorbitol dehydrogenase
[77]. Myoinositol competes with glucose for cellular uptake,
and it is also excreted in the urine in excessive amounts in
diabetic patients [76]. However, cellular depletion of myoinosi-
tol occurs selectively and involves those tissues predisposed to
developing diabetic complications, such as the lens, the retina,
peripheral and autonomic nerves, and the kidney. The impor-
tance of myoinositol lies in the fact that it is a key precursor of
cell membrane inositol phospholipids. In recent years, a large
number of diverse calcium-mobilizing ligands have been found
to initiate their actions by receptor-mediated hydrolysis of cell
membrane phospholipids. Thus, the vasoconstricting effects of
angiotensin II and norepinephrine on vascular smooth muscle,
for example, are initiated by hormone-receptor activation of
cell membrane phospholipase C (PLC). Plasma membrane
phosphoinositides are hydrolyzed by PLC to several inositol
phosphates and 1,2 diacylglycerol (DAG). Inositol triphosphate
(1P3) and DAG act in concert to raise intracellular calcium
concentration and to activate protein kinase C (PKC). The
latter is one of several protein kinases capable of phosphoryla-
tion of myosin light chains and thus of sustaining smooth
muscle contraction [77]. In view of these well-recognized
biochemical events, a reasonable hypothesis to explain diabetic
hyperfiltration is that contractile cells within the kidney become
depleted of myoinositol, and that cell membrane turnover of 1P3
and DAG are thereby impaired. This in turn would be expected
to limit hormone-stimulated increases in intracellular calcium
and activation of PKC. As a result, phosphorylation of myosin
light chain would be impaired, as would sustained smooth
muscle tone.
Although the sequence of events stemming from cellular
myoinositol depletion provides a logical framework for this
hypothesis, several recent observations require significant mod-
ification of the theory. Lee and coworkers found that retinal
endothelial cells accumulate sorbitol in response to high glucose
concentrations, indicating the presence of aldose reductase, but
that PKC activity in membrane fractions actually increases
markedly at the same time that the cytosolic fraction of PKC
decreases [78]. The addition of sorbinil, an aldose reductase
inhibitor, to the endothelial cell preparation blocked sorbitol
accumulation but did not influence PKC activity. On the other
hand, Na-K-ATPase was inhibited markedly in the presence
of hyperglycemia, and this inhibition was prevented by sorbinil
[78]. The same laboratory found that, because of increased
formation of its precursors, diacyiglycerol synthesis is actually
increased in the presence of elevated glucose, not decreased as
predicted by the myoinositol depletion hypothesis [79]. The
increased diacylglycerol is thought to be responsible for the
greater PKC activity in the cell membranes. Craven and DeRu-
bertis, using isolated glomeruli from diabetic rats, found that
despite a reduced inositol content and decreased polyphospho-
inositide turnover, PKC was increased in particulate cell frac-
tions and that this increase was prevented by insulin treatment
[80]. They also found that glucose increased the production of
diacylglycerol. Thus, considerable evidence militates against
the hypothesis that a deficiency of diacylglycerol or PKC
underlies impaired vascular smooth muscle tone in diabetes.
Evidence remains, however, that hyperglycemia inhibits Na-
K-ATPase activity, and that this alteration can be corrected
by the inhibition of aldose reductase. It is possible that mem-
brane depolarization occurs, secondary to impaired Na-K
transport, which effects transmembrane calcium flux. Further
studies are needed to clarify the relationship between myoinosi-
to!, NaKtATPase, and smooth muscle function.
Aldose reductase has been found in various locations in the
kidney both by staining methods [85, 86] and biochemical
methods [87, 88]. Kikkawa and coworkers found both aldose
reductase and sorbitol dehydrogenase activity in crude homoge-
nates of cultured mesangial cells [88]. Incubation of mesangial
cells in medium containing 55 mM glucose resulted in a large
intracellular accumulation of sorbitol. The accumulation was
blocked by the addition of an aldose reductase inhibitor. These
in-vitro biochemical data strongly suggest that sorbito! concen-
trations rise in the glomeruli in the presence of elevated
glucose, and that aldose reductase inhibitors correct this abnor-
mality.
Evidence for an important role for the polyol pathway in
influencing vascular tone was recently reported by Williamson
et al [89]. These authors exposed rat blood vessels in a
granulation tissue-skin chamber to high concentrations of glu-
cose. They found that with 30 mM D-glucose in the chamber,
but not L-glucose, blood flow increased markedly, as did tissue
sorbitol concentrations. Addition of the aldose reductase inhib-
itor tolrestat to the chamber prevented the increase in both
sorbitol concentration and blood flow. Renal hemodynamic
studies have investigated the role of sorbitol accumulation
and/or myoinositol depletion in the hyperfiltration of early
diabetes. Goldfarb et a! first reported that an aldose reductase
inhibitor (sorbinil) or dietary myoinositol supplementation pre-
vented hyperfiltration in diabetic rats [90]. In untreated diabetic
rats, GFR was 11.0 ml/minlkg body weight, 9.4 mI/mm/kg in a
group fed 1.0% myomnositol, and 8.8 mI/mm/kg in diabetic rats
given sorbinil (25 mg/kg/day). Several other groups of investi-
gators confirmed that aldose reductase inhibitors prevent hy-
perfiltration in diabetic rats. Craven and DeRubertis found that
sorbinil reduced GFR from 7.5 to 4.5 mllmin/kg in diabetic rats,
but that the drug had no effect in normal rats [91]. They also
found that sorbinil normalized elevated PGE2 and 6-keto-PGF1
production in isolated diabetic glomeruli but had no effect on
normal glomeruli. They postulated that sorbinil might prevent
hyperfiltration by suppressing glomerular synthesis of vasodila-
tory prostaglandins. Frey et al also reported that sorbinil affects
PGE, production [92]. In rats with STZ-induced diabetes,
urinary PGE2 was elevated during the first 2 weeks of diabetes
in untreated rats but returned to normal when sorbinil was fed
to the animals. The authors did not measure GFR. Williamson
and colleagues did measure GFR using 57Co-EDTA in diabetic
rats and found GFR to be double that of normal control rats
[93]. Treatment with either of two aldose reductase inhibitors
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(sorbinil or toirestat) prevented the hyperfiltration. Tilton and
colleagues reported that 3 structurally different aldose reduc-
tase inhibitors blocked diabetic-induced increases in renal
blood flow and GFR in rats [94]. In our laboratory, sorbinil fed
to rats with STZ-induced diabetes in a diet rationed to 20 glday
prevented the increase in SNGFR, QA and SNBF [18]. Plasma
renin activity, blood glucose, and glomerular angiotensin II
receptor density were not affected by sorbinil treatment [18].
Sorbinil did, however, alter glomerular hemodynamics in nor-
mal rats: single-nephron filtration fraction, stopped flow pres-
sure, and RA were slightly but significantly higher than in
untreated normal rats [18]. These observations raise the possi-
bility that sorbinil has an effect on vascular tone separate from
its major role as an aldose reductase inhibitor. This possibility
is raised by observations by Cohen and Klepser, who found
glomerular Na-K-ATPase activity to be reduced in isolated
glomeruli of rats in early stages of diabetes (less than 18 days),
but not at later stages (more than 3 weeks) [95]. The in-vitro
addition of sorbinil directly stimulated Na-K-ATPase activ-
ity in normal glomeruli but not in diabetic glomeruli. These
researchers suggested that sorbinil might have a membrane-
associated effect in normal glomerular tissue independent of its
aldose-reductase inhibiting property. Thus, it is possible that
the prevention of hyperfiltration induced by sorbinil, and per-
haps other aldose reductase inhibitors, is mediated not only by
correction of sorbitol and myoinositol tissue levels, but also by
a membrane-associated effect on NatKATPase and reduc-
tion in vasodilatory prostaglandins.
Not all investigators agree that aldose reductase inhibitors
prevent hyperfiltration. Daniels and Hostetter administered
ponalrestat (Statil) in a daily dose of 25 mg/kg body weight to
rats with STZ-induced diabetes. Untreated diabetic rats had a
significantly higher GFR than did normal controls, but ponal-
restat had no significant effect on the hyperfiltration 3 to 5
weeks after the onset of diabetes [96]. The drug did reduce red
blood cell and kidney sorbitol levels significantly, indicating its
effectiveness as an aldose reductase inhibitor. The authors
suggested that the reductions in GFR found by other investiga-
tors with aldose reductase inhibitors might be due to effects
independent of their enzyme-inhibiting action, such as inhibi-
tion of prostaglandin synthesis or direct membrane effects. In
spite of the controversial data, most evidence supports the view
that hyperfiltration can be prevented by aldose reductase inhi-
bition or myoinositol supplements.
Hyperglycemia and extracellular fluid volume
Does hyperglycemia cause vasodilation by an osmotic effect
on the cells lining small blood vessels? Osmotic transfer of
water from the intracellular compartment would be expected to
shrink the lining cells, thereby enlarging the cross-sectional
diameter of the lumen [97]. However, the effect of glucose
appears to be greater than can be accounted for by its osmotic
pressure. Thus, Williamson et al demonstrated that L-glucose
does not dilate microvessels, whereas D-glucose does [89]. In
clinical studies, Brochner-Mortensen [7] and Bell et al [56]
found hyperfiltration to be present more often in poorly con-
trolled diabetic patients than in those with improved blood
glucose levels. Moreover, improved glycemic control by insulin
reduces or even normalizes hyperfiltration [98—103]. Wiseman
et al evaluated glycemic control in diabetic patients by moni-
toring the level of glycosylated hemoglobin (HbA1) [99]. With
improved metabolic control, HbAIC fell into the normal range.
The GFR became normal in 4 of 6 patients. Similarly, Chris-
tiansen found a significant correlation between HbAIC and GFR
in 28 insulin-dependent diabetics who did not have significant
albuminuria [100]. Christiansen et a! also reported that during
the first week of insulin treatment in newly diagnosed IDDM
patients, GFR and RPF fell consistently, whereas kidney vol-
ume, evaluated by ultrasound, did not change [101]. In an
earlier study, Mogensen and Andersen measured GFR, RPF,
and kidney size (by x-ray) over a 3-month period in 6 newly
diagnosed patients treated with insulin [4]. The GFR fell con-
sistently in this time period, and renal size also decreased
slightly but significantly. That the effect on renal hemodynamics
was not due to insulin administration per se but rather to the fall
in blood glucose was suggested by acute studies carried out by
Christiansen et al [102]. Insulin infusion for 2 hours in diabetic
subjects lowered GFR and RPF only if blood glucose was
allowed to fall. If blood glucose was maintained constant,
insulin administration had no effect on GFR or RPF. Richards
and colleagues found that one month of rigorous control of
blood glucose in diabetic patients significantly lowered blood
pressure but produced no changes in PRA, aldosterone, or
catecholamine levels [103]; these findings imply that hormonal
changes were not responsible for the normalization of renal
hemodynamics. Strict metabolic control also prevents hyperfil-
tration and a rise in P in rats with STZ-induced diabetes [54,
1041. In animal and human studies in which the effect of "tight"
metabolic control on diabetic hyperfiltration was examined, the
weight of evidence consistently indicates that improved glyce-
mic control is accompanied by a fall in the elevated GFR [4, 54,
99, 100, 102, 104].
The mechanism by which poor glycemic control contributes
to hyperfiltration is not understood, but evidence indicates that
acute changes in blood glucose produce only small effects
[105—107]. Christiansen et al studied euglycemic diabetics by
infusing glucose to raise blood glucose from 4.2 to 15.2 mmoll
liter [105]. The GFR rose acutely but only slightly, from 128 to
132 ml/min, and RPF increased from 534 to 562 mI/mm.
Wiseman and coworkers infused dextrose into diabetic patients
with and without hyperfiltration and into normal controls and
found that raising blood glucose from 5—6 mmollliter to 12.5
mmollliter significantly increased GFR only in the hyperfiltering
diabetic subjects (from 157 to 174 mllmin), not in the other 2
groups [106]. In the isolated perfused rat kidney, Kasiske and
colleagues found that raising glucose to 500 mg/dl in the
perfusate led to immediate vasodilation and a small but signif-
icant increase in GFR [107]. Indomethacin blocked this effect.
Thus, considerable evidence suggests that either the level of
blood glucose, or another factor associated or correlated with
chronic hyperglycemia, can contribute to glomerular hyperfil-
tration in diabetes. In contrast, Ditzel et al [2] and Mogensen
[108] were unable to find any correlation between spontaneous
blood glucose and GFR. Moreover, in normal subjects whose
blood sugar levels were raised to 600—700 mg/dl, GFR was not
affected [108]; this finding concurs with Wiseman et al's report
[106]. Acute elevation of blood glucose might not lead immedi-
ately to hyperfiltration. Chronically elevated blood glucose
might influence GFR by indirect mechanisms, however.
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Fig. 6. Schematic representation of effects of
increased filtered load of glucose on proximal
tubular sodium and water reabsorption.
Recent observations point to the possible existence of impor-
tant, indirect effects of hyperglycemia on GFR. Blantz et al
studied tubuloglomerular feedback (TGF) in normal rats during
perfusions of the loop of Henle with tubular fluid containing
high concentrations of glucose [1091. They found a significant
inhibition of TGF, in that SNGFR did not fall as much as when
the ioop was perfused with non-glucose-containing tubular
fluid. Woods et al studied TGF in normal dogs infused in-
trarenally with glucose [110]. In dogs with filtering kidneys,
GFR and RBF rose 18% to 19%, whereas in dogs with non-
filtering kidneys (due to ureteral ligation), intrarenal infusion of
glucose had no effect on RBF. These observations indicated
that the filtered load of glucose, rather than the blood level of
glucose, influenced renal hemodynamics. The authors postu-
lated that filtered glucose reaching the distal nephron somehow
suppresses TGF. Further evidence for a role for filtered glucose
comes from studies of electrolyte reabsorption by the renal
tubules of diabetic children [1111. Filtered sodium and tubular
reabsorption of sodium were significantly higher in diabetic
children than in matched controls, and the authors postulated
that this increase was due to enhanced sodium-coupled glucose
reabsorption (co-transport). They also suggested that the aug-
mented renal tubular sodium reabsorption was important as a
mechanism leading to elevated GFR in diabetes. Brochner-
Mortensen and colleagues measured lithium clearance in young
adults with IDDM [112]. Lithium is thought to be reabsorbed
primarily in the proximal tubule, and thus its urinary clearance
can be used as a measure of fluid leaving the end of the proximal
tubule. The difference between filtered and excreted lithium is
taken as a measure of proximal tubule sodium reabsorption.
The researchers found evidence for increased filtered sodium
and water, increased absolute and fractional reabsorption of
sodium and water in the proximal tubule, and unaltered distal
delivery of fluid. More recently, Wiseman et al measured
sodium reabsorption in hyperfiltering diabetics during euglyce-
mia and hyperglycemia induced by intravenous glucose infusion
[106]. As GFR rose, total sodium reabsorption increased,
whereas free-water clearance fell. The decrease in free-water
clearance suggests that the increase in sodium reabsorption
during hyperglycemia occurred proximal to the diluting seg-
ment. A relative reduction in the distal delivery of sodium might
have limited free-water clearance. In accord with these findings
are those of Hannedouche et al, who measured lithium clear-
ance in type-l diabetics and confirmed higher absolute and
fractional reabsorption of sodium in the proximal tubule of
diabetic versus control subjects as well as a decrease in distal
sodium delivery [1131. Both groups of investigators postulated
that decreased delivery of sodium to the macula densa might
suppress TGF and thus contribute to hyperfiltration of diabetes.
Using microperfusion methods, we recently studied the effect
of progressive elevation of glucose concentrations in the lumen
of the proximal tubule on sodium and water absorption [114].
We found both in normal and diabetic rats that the addition of
100 mg/dl, 300 mg/dl, and 500 mg/dl of glucose to an isotonic
electrolyte solution progressively stimulated sodium and water
absorption. Rates of absorption plateaued at glucose concen-
trations of 300—500 mgldl. The increased sodium reabsorption
appeared to be mediated by the brush-border sodium/glucose
co-transporter. In addition, the osmolality of the collected fluid
fell to hypotonic levels and resulted in an exaggerated transtu-
bular osmotic gradient. This gradient presumably acted as a
passive driving force for increased water absorption. These
observations are depicted in Fig. 6. Our findings support the
view that poor glycemic control, by increasing the concentra-
tion of glucose in the proximal tubule, increases sodium and
water absorption. This effect in turn could lead to extracellular
fluid volume expansion. Total exchangeable body sodium is
increased in diabetics in the absence of intrinsic renal disease
[115, 116], although blood and plasma volumes are not always
elevated. The effect of intraluminal glucose on sodium reab-
sorption is immediate; thus one can postulate that even short,
intermittent periods of hyperglycemia in a relatively well-
controlled diabetic can produce increases in total-body sodium
that in turn could suppress the renin-angiotensin system. Ele-
vation of plasma ANP also would be a consequence of this
volume expansion. The combination of volume expansion, a
suppressed renin-angiotensin system, and elevated ANP is
distinctly unusual; in most other sodium-retaining conditions
Osmotic gradient Osmotic gradient
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Table 3. Hypothetical consequences of increased glucose-mediated
proximal sodium and water reabsorption
Increase in total-body sodium
Extracellular fluid volume expansion
Suppression of renin-angiotensin system
Elevation of ANP
Hypoaldosteronism
Hypertension
Renal hypertrophy
Decreases in distal sodium delivery
Impaired free-water clearance
Impaired K secretion
Impaired H secretion
such as congestive heart failure, cirrhosis of the liver, and
nephrotic syndrome, the renin-angiotensin system often is
stimulated rather than suppressed. The triad of volume expan-
sion, elevated ANP, and angiotensin suppression might play a
critical role in hyperfiltration in early diabetes. Other possible
consequences of glucose-mediated, stimulated proximal sodium
and water absorption are listed in Table 3.
Conclusions
No single mechanism is likely to account for the hyperfiltra-
tion of early diabetes. Numerous abnormalities have been
documented that could play a role, including reduced receptor
density for angiotensin II and thromboxane A2, increased
urinary kallikrein, and increased prostaglandin production.
However, experimental studies have not shown unequivocally
that any of these abnormalities are critical for diabetic hyper-
filtration. On the other hand, there is substantial evidence both
in diabetic humans and in animals that improved glycemic
control corrects or prevents hyperfiltration. Improved glycemic
control leads to correction of a number of disturbances, includ-
ing a reduction in volume, reduction of ANP, a decrease in
serum osmolality, correction of tubulo-glomerular feedback,
and correction of prostaglandin overproduction; in addition, the
provision of insulin to achieve glycemic control also increases
calcium entry into vascular smooth muscle cells. Thus, the
unifying factors leading to a large number of abnormalities
appear to be hyperglycemia and insulin deficiency itself. Poorly
controlled glycemia is most likely the starting point for the
cascade of signal-receptor-transduction abnormalities resulting
in the hyperfiltration of diabetes.
Questions and answers
DR. JORDAN J. COHEN (Dean, State University of New York
at Stony Brook, Stony Brook, New York): As you indicated, the
degree of hyperfiltration in the early stages of diabetes can be
quite striking, with glomerular filtration rates 70%, 80%, or
even 100% higher than normal. You suggested that this hyper-
filtration simply might be a reflection of chronic volume expan-
sion resulting from a stimulation of glucose-dependent sodium
reabsorption triggered by the high filtered load of glucose. This
possibility would be strengthened if other forms of chronic
volume expansion—notably primary aldosteronism, chronic
DOCA administration, or SIADH—were associated with such
extreme elevations of GFR. Do we know from any of these
circumstances what the relationship is between the magnitude
of the chronic volume expansion and the resulting degree of
hyperfiltration? Also, I wonder how much volume expansion
one might reasonably expect to see on a chronic basis from
augmented glucose-dependent sodium reabsorption, given that
"escape" from sodium retention would be anticipated to occur
as a result of the dampening effects of other regulatory pro-
cesses on sodium reabsorption.
DR. BANK: I did not intend to imply that diabetic hyperliltra-
tion can be accounted for solely by glucose-stimulated sodium
and water reabsorption, as several other important abnormali-
ties co-exist that could contribute to reduced vascular tone.
However, sodium and water retention might account for de-
creased renin-angiotensin levels and the elevation of ANP in
diabetics. It is difficult to compare degrees of sodium retention
in diabetes versus primary hyperaldosteronism, because careful
balance studies under similar controlled conditions have not
been carried out to compare these two conditions. In fact,
studies of diabetic patients vary considerably in their findings.
The most consistent finding in diabetes has been an increase in
total-body sodium, whereas intravascular volume has been
reported to be increased in some studies but not in others.
Capillary leakage of proteins might account for some of the
discrepancies among published reports and also might result in
expansion of interstitial volume at the expense of plasma
volume. It is clear that both in diabetes and hyperaldoster-
onism, a new steady state of sodium and water balance must be
reached. What the counterregulatory mechanisms are is not
clear, although elevation of ANP could play a role in both
conditions. Hypertension in primary hyperaldosteronism also
could be a factor in the "escape" phenomenon. The level of
increase in total-body sodium at the time that balance is
restored could depend on these counterregulatory mechanisms.
In addition, glucose-mediated sodium reabsorption is quantita-
tively much greater than aldosterone-mediated sodium reab-
sorption, because the former takes place in the proximal
convoluted tubule, whereas the latter occurs in more distal
segments of the nephron. But whether this difference results in
greater total-body sodium in diabetes versus hyperaldoster-
onism is not clear. It is generally held that the volume expan-
sion due to primary hyperaldosteronism, chronic DOCA admin-
istration, and SIADH is associated with hyperfiltration, but the
increase in GFR is not as great as in diabetes.
DR. NSCOLAOS E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): Evi-
dence has implicated an increase in plasma ANP concentration
in the phenomenon of mineralocorticoid escape El 17].
DR. BANK: Atrial natriuretic peptide secretion is generally
increased in volume-expanded states, and ANP might be impli-
cated in the "escape" phenomenon seen with chronic mm-
eralocorticoid administration. In diabetes, ANP has been found
to be elevated, both in humans and experimental animals.
Although not proven, the elevated ANP might play a role in
limiting progressive volume expansion by inhibiting distal so-
dium reabsorption.
DR. JEROME P. KASSIRER (Associate Physician-in-Chief,
New England Medical Center, Boston, Massachusetts): What
is the clinical significance of the increase in filtration in early
diabetes? Is there a more rapid decline in renal function in these
patients as compared with those whose blood sugars are well
controlled and who do not have hyperfiltration?
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DR. BANK: There are few published studies in which diabet-
ics with and without hyperfiltration were followed over a period
of years to determine whether early hyperfiltration eventuated
in the development of nephropathy [8, 9, 100]. Although the
number of patients studied was small, there was a definite
correlation between early hyperfiltration and the onset of
proteinuria some years later. In my view, more patients need to
be studied longitudinally to confirm these findings.
DR. COHEN: In type-I! diabetes, insulin levels often are quite
high. This fact might be useful in pin-pointing the role of insulin
per se in hyperfiltration. Is hyperfiltration a feature of the early
course of patients with type-I! diabetes?
DR. BANK: Renal function data in early type-Il diabetes has
been more difficult to come by, because the onset of diabetes is
more difficult to date. Moreover, type-IT diabetes, which occurs
mostly in older individuals, is often complicated by other
illnesses, such as essential hypertension or cardiovascular
disease, which could affect glomerular filtration rate. However,
a recent abstract reported elevated GFR and renal blood flow in
patients with poorly controlled type-Il diabetes [1181.
DR. PAUL KURTIN (Director, Dialysis Unit, New England
Medical Center): To follow up on that question, are there any
glucose-insulin clamp studies that separate out the effects of
insulinopenia from those of hyperglycemia?
DR. BANK: In a 1981 study, insulin was infused into type-I
diabetics, and glucose was either allowed to fall into the normal
range or was "clamped" at a fixed level [102]. Glomerular
filtration rates fell only when glucose was allowed to fall, but
not when the blood glucose level was "clamped." This study
suggests that insulin is not itself responsible for the hyperfiltra-
tion.
DR. JAMES STROM (Department of Nephrology, St. Eliza-
beth's Hospital of Boston, Brighton, Massachusetts): Could
one correct the hyperfiltration by inducing negative sodium
balance in the animals, for example, with diuretics?
DR. BANK: In our study of a low-sodium diet in diabetic rats
[17], a natriuresis did occur during the first day that dietary
sodium was reduced. This was not observed in normal controls.
We did not administer a diuretic, and the mechanism for the
sodium loss was not clear. It might have been due to ANP,
which is elevated in diabetic rats. In any case GFR, when
measured several days later, had fallen into the normal range.
Perhaps a similar result would occur with administration of a
diuretic, although we have not performed that experiment. We
believe that the fall in GFR was mediated by stimulation of the
renin-angiotensin system, as saralasin infusion caused GFR to
rise again to hyperfiltration levels. I am not aware of any human
studies in which either a low-sodium diet or diuretics have been
tried for diabetic hyperfiltration.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): You mentioned
that ANP increases resistance in the efferent arteriole, just as
angiotensin II does. If a maximum amount of angiotensin II is
present at the efferent arteriole, does ANP have an additive
effect?
DR. BANK: I have not seen such a study. It is well established
that ANP generally acts as an antagonist to the renin-angioten-
sin system, and that it counteracts the vasoconstrictor effect of
angiotensin II on vascular smooth muscle. An exception is the
efferent arteriole, where both ANP and angiotensin II appear to
cause constriction. The second messenger systems for these
two hormones are different. Angiotensin II activates phospho-
lipase C, which generates inositol phosphate isomers and DAG,
and also increases the influx of extracellular calcium. Atrial
natriuretic hormone, on the other hand, activates guanylate
cyclase, and leads to a rise in intracellular cyclic GMP. One
might anticipate, based on these considerations, that the effects
of angiotensin II and ANP on the efferent arteriole might be
additive.
DR. MADIAs: I would like to return to the sodium issue. In
your experiments, placing hyperfiltering rats with streptozoto-
cm-induced diabetes on a low-salt diet returned GFR to the
normal range. I was wondering whether you have observations
on animals being placed on salt restriction concomitantly with
the induction of the diabetic state to assess whether prevention
of volume expansion prevents the development of hyperfiltra-
tion and subsequent renal disease.
DR. BANK: That experiment has not been tried, to my
knowledge.
DR. MADtAS: I find the experiment by Ortola and colleagues
very impressive in suggesting that ANP might be important in
the hyperfiltration of experimental diabetes. In discountenanc-
ing its potential role, you cited the disparate hemodynamic
effects of ANP when it is administered to normal subjects as
compared with the hemodynamic profile of the diabetic state. I
would argue, however, that the hemodynamic effects of ANP
might be different when administered to diabetic animals. Do
we know what the hemodynamic effects of ANP are when it is
administered to diabetic animals with euglycemia, a state in
which plasma levels of endogenous ANP are normal?
DR. BANK: I am not aware of experiments in which ANP has
been administered to euglycemic diabetic animals. Hyperfiltra-
tion and endogenous ANP levels become normal when diabetic
rats are made euglycemic by long-acting insulin [54]. It would
be interesting to infuse ANP under those conditions to deter-
mine whether hyperfiltration recurs. One would have to be
careful to administer doses within the range found in hyperfil-
tering diabetic animals. Larger, pharmacologic doses in normal
animals induce hyperfiltration, whereas physiologic doses of
ANP have relatively small effects on GFR.
DR. RONALD PERRONE (Divison of Nephrology, New En-
gland Medical Center): You've indicated that you believe
hyperglycemia to be the ultimate explanation for all of the
hyperfiltration in early diabetes. Yet insulin pump therapy
doesn't always normalize GFR and doesn't reverse renal hy-
pertrophy [99]. Do you think that's because the insulin pump
doesn't yield perfect glycemic control, or do you think other
factors are involved?
DR. BANK: In most studies on glycemic control, both in
humans and rats with diabetes, GFR did fall to or toward the
normal range. The weight of evidence is that this takes time to
occur, that is, days to weeks. There are fewer reports of renal
hypertrophy being reversed by control of hyperglycemia. Some
studies have shown regression of hypertrophy, whereas others
have not. These discrepancies might be due in part to the
inexact methods used for measuring renal size in humans.
Alternatively, renal hypertrophy, once established, might be
permanent or take a very long time to regress.
DR. KURTIN: I'd like to return to Dr. Cohen's first question.
804 Nephrology Forum: Diabetic hyperfiltration
Glucocorticoids do increase GFR. Children with minimal-
change disease treated with glucocorticoids can have a GFR as
high as 180—200 mllmin/1 .73 m2 (personal observation). Would
you please comment on hyperfiltration that might be seen with
glucocorticoids as compared with mineralocorticoids?
DR. BANK: Glucocorticoids are known to have a direct effect
on renal vasculature, causing vasodilation and increases in
GFR. The issue raised by Dr. Cohen was whether excess
mineralocorticoids, that is, aldosterone and DOCA, which lead
to volume expansion, cause marked elevations of GFR, as in
diabetics. These agents do not, but on the other hand, volume
expansion is probably not as great as in diabetes.
DR. KURTIN: Dr. Lance Dworkin has reviewed various
hormonal effects on GFR. Glucocorticoids increase GFR via an
increase in blood flow. This effect can be seen acutely and thus
might not be a volume effect [119].
Da. HARRINOTON: I'd like to return to Dr. Kassirer's ques-
tion. Why do we care about the hyperfiltration? You mentioned
that approximately 45% of patients with diabetes develop renal
failure, yet the remaining 55% do not. Is there a substantial
difference in the degree of early hyperifitration between those
who progress and those who do not?
DR. BANK: As I mentioned, a few studies have followed
diabetic patients from the early onset of diabetes over 7 to 10
years. The patients who had higher GFR values at the beginning
of the observation period developed proteinuria and declining
GFR, as compared with patients who initally had a more normal
GFR. Because of the evidence I presented that improved
glycemic control lowers GFR, we might assume that the hyper-
filtering patients also had poor glycemic control. If that assump-
tion is correct, then multiple abnormalities associated with poor
glycemic control could have contributed to developing diabetic
nephropathy, not necessarily hyperfiltration alone. In other
words, the hyperfiltration might be a marker of poor glycemic
control. The patient discussed today exemplifies this situation.
He had hyperfiltration, but he also had very poor glycemic
control and persistently elevated glycosylated hemoglobin. It is
therefore difficult to attribute his progressive proteinuna and
renal impairment to hyperfiltration alone. Another factor that
pertains to this discussion is the marked difference between
blacks and whites in the development of end-stage renal failure
due to diabetes. It is not known whether the higher incidence in
blacks is due to hereditary factors or to substandard medical
care.
DR. RONALD LECHAN (Division of Endocrinology, New
England Medical Center): Cytokines such as IL-6 have been
identified in endothelial cells as well as in vascular smooth
muscle cells. Could they be contributing to renal blood flow,
and might they be affected by hyperglycemia?
DR. BANK: I have not seen any studies on vascular IL-6
effects on renal blood flow, nor on effects of hyperglycemia on
IL-6.
DR. ANDaw S. LEVEY (Division of Nephrology, New En-
gland Medical Center): I would like to again refer to the
question of hyperfiltration and its correlation with the progres-
sion to renal disease. Do all diabetics with early-onset disease
manifest a phase of hyperfiltration, or does this only occur in
the subpopulation that later develops nephropathy?
DR. BANK: The patients who had hyperfiltration developed
evidence of nephropathy, whereas those with lower GFRs did
not, at least during the time they were followed.
DR. LEVEY: That's a little different than what I meant. In the
study by Mogensen and Christiansen, patients were initially
selected on the basis of whether their renal disease had pro-
gressed; the two groups were then compared [120]. My question
is, among a cohort of patients with new-onset diabetes, is the
distribution of GFR normal or biomodal, and does a larger
subgroup have hyperfiltration?
DR. BANK: To my knowledge, GFR has not been measured in
a sufficiently large number of patients with recent-onset diabe-
tes to allow us to define its distribution. The published data
include a considerable spread in values, the mean being higher
than in normal controls. There does not seem to be a bimodal
distribution, but rather a normal distribution that is displaced
toward higher values. The data have to be evaluated, however,
in light of previous insulin therapy and glycemic control,
because both could influence the GFR.
DR. HARRINGTON: Can you relate the rise in GFR to differ-
ences in blood sugar, hemoglobin A1C, or anything else? You
might not be able to do such a study because as the hypergly-
cemia is corrected, the GFR also is corrected. You would, in
fact, probably need to measure the GFR on day 1.
DR. BANK: That is correct. Most of the measurements
reported in the literature have been in treated diabetics with
variable degrees of glycemic control. Christiansen et al mea-
sured GFR in patients during the first week of insulin therapy
[101]. In that study, all patients were hyperfiltering before
receiving insulin, and GFR fell with insulin treatment. This
suggests that in untreated diabetes, hyperfiltration is quite
common, and that measurements made after treatment has been
started will vary according to the level of glycemic control. In
experimental rats with streptozotocin-induced diabetes, hyper-
filtration is uniformly present when blood glucose ranges be-
tween 300 and 400 mgldl, but filtration becomes normal after
euglycemia has been achieved by insulin therapy.
Reprint requests to Dr. N. Bank, Renal Division, Montefiore Hospi-
tal and Medical Center, 111 East 210th Street, Bronx, New York 10467,
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